Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 20, 2015, 43 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $78.70 to $1,311,864,574.80.

Highlighted Stocks Traded by Insiders:

Ameriprise Financial (AMP) - FREE Research Report

Junek John Carl, who is Exec VP and General Counsel at Ameriprise Financial, sold 2,682 shares at $129.81 on April 20, 2015. Following this transaction, the Exec VP and General Counsel owned 17,030 shares meaning that the stake was reduced by 13.61% with the 2,682-share transaction.

The shares most recently traded at $130.23, up $0.41, or 0.32% since the insider transaction. Historical insider transactions for Ameriprise Financial go as follows:

  • 4-Week # shares sold: 12,521
  • 12-Week # shares sold: 205,955
  • 24-Week # shares sold: 259,042

The average volume for Ameriprise Financial has been 1.2 million shares per day over the past 30 days. Ameriprise Financial has a market cap of $23.6 billion and is part of the financial sector and financial services industry. Shares are down 1.29% year-to-date as of the close of trading on Monday.

Ameriprise Financial, Inc., through its subsidiaries, provides various financial products and services to individual and institutional clients in the United States and internationally. The stock currently has a dividend yield of 1.8%. The company has a P/E ratio of 15.6. Currently, there are 6 analysts who rate Ameriprise Financial a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMP - FREE

TheStreet Quant Ratings rates Ameriprise Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Ameriprise Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medicines Company (MDCO) - FREE Research Report

O'Connor William Bernard, who is SVP & Chief Acct. Officer at Medicines Company, sold 1,281 shares at $30.00 on April 20, 2015. Following this transaction, the SVP & Chief Acct. Officer owned 24,732 shares meaning that the stake was reduced by 4.92% with the 1,281-share transaction.

The shares most recently traded at $27.59, down $2.41, or 8.74% since the insider transaction. Historical insider transactions for Medicines Company go as follows:

  • 4-Week # shares sold: 34,773
  • 12-Week # shares sold: 42,327
  • 24-Week # shares sold: 42,327

The average volume for Medicines Company has been 1.3 million shares per day over the past 30 days. Medicines Company has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are down 0.83% year-to-date as of the close of trading on Monday.

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. Currently, there are 2 analysts who rate Medicines Company a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDCO - FREE

TheStreet Quant Ratings rates Medicines Company as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Medicines Company Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Memorial Production Partners (MEMP) - FREE Research Report

MRD Holdco LLC, who is Shareholder at Memorial Production Partners, sold 508,735 shares at $17.08 on April 20, 2015. Following this transaction, the Shareholder owned 190,514 shares meaning that the stake was reduced by 72.75% with the 508,735-share transaction.

The shares most recently traded at $17.19, up $0.11, or 0.62% since the insider transaction. Historical insider transactions for Memorial Production Partners go as follows:

  • 4-Week # shares bought: 6,120
  • 4-Week # shares sold: 16,000
  • 12-Week # shares bought: 6,120
  • 12-Week # shares sold: 16,000
  • 24-Week # shares bought: 81,620
  • 24-Week # shares sold: 16,000

The average volume for Memorial Production Partners has been 827,100 shares per day over the past 30 days. Memorial Production Partners has a market cap of $1.4 billion and is part of the basic materials sector and energy industry. Shares are up 17.96% year-to-date as of the close of trading on Monday.

Memorial Production Partners LP, through its subsidiary, engages in the acquisition, development, exploitation, and production of oil and natural gas properties. The stock currently has a dividend yield of 12.93%. The company has a P/E ratio of 10.2. Currently, there are 7 analysts who rate Memorial Production Partners a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MEMP - FREE

TheStreet Quant Ratings rates Memorial Production Partners as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Memorial Production Partners Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research

null